Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-13.3
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
Full year2024年６月１日〜2025年５月31日ConsolidatedJapanese GAAPNet Sales64,486¥ millionYear on year +4.8%Progress 95.3%
Operating profit838¥ millionYear on year -13.3%Progress 142.0%
Ordinary income909¥ millionYear on year -10.9%Progress 143.8%
Net income attributable to owners of the parent616¥ millionYear on year +6.3%Progress 174.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share249.79円
Operating MarginCurrent fiscal year 1.3 % / Previous period 1.6 %
Financial position at period-end
Total assets27,549¥ million
of which net assets 8,988 ¥ millionEquity ratio 32.6%vs. prior year-end +0.4pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+617
Investment+19
Financials-240
Net change+396
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥5,698 million
Segment revenueMedical device sales ¥64,487 million (YoY +4.8%), Medical Equipment Manufacturing and Sales ¥219 million (YoY -18.0%), Medical Mall Business ¥72 million (YoY +6.4%)
Segment profitMedical device sales ¥2,198 million (YoY +1.2%), Medical Equipment Manufacturing and Sales ¥-220 million, Medical Mall Business ¥5 million (YoY +750.6%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥67,647 million (YoY +4.9%)
Operating profit¥590 million (YoY -29.6%)
Ordinary income¥632 million (YoY -30.5%)
Net income¥354 million (YoY -42.6%)
Annual Dividend Forecast¥70 per share → ¥70 per share（0.0%）
Payout ratioCurrent fiscal year 30 % / Next-year forecast 49 %
Shareholder Return PolicyBasically based on a consolidated dividend payout ratio of 30%
Factors Behind Changes in Business Performance
売上高は、放射線機器等の設備投資需要の増加、検査・手術件数の増加、株式会社鹿児島オルソ・メディカルの整形外科分野の売上増加等により増加した。利益面では、賃上げによる人件費2億20百万円の増加、物流コスト6千万円の上昇、マイクロソニック株式会社の研究開発費1億64百万円の計上等により販売費及び一般管理費が増加し、営業利益及び経常利益は減少した。
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationMaterial changes No / New Number of companies 1 / Company name Microsonic Corporation / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsNo applicable matters.
Impairment lossNone in the current period
Breakdown of extraordinary income (loss)Extraordinary income Item Reversal of allowance for doubtful accounts / Amount ¥36 million / Extraordinary loss Item Loss on step acquisition / Amount ¥3 million
Depreciation and amortization¥180 million
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNone (対象者：Not applicable)
Issued Shares at Period-End2,553,000 Shares
Treasury Shares at Period-End86,958 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年６月１日〜2025年５月31日 |
| Net Sales | ¥64,486 million (YoY +4.8%) |
| Operating profit | ¥838 million (YoY -13.3%) |
| Ordinary income | ¥909 million (YoY -10.9%) |
| Profit attributable to owners of the parent | ¥616 million (YoY +6.3%) |
| Net income per share | 249.79円 |
| Operating Margin | Current fiscal year 1.3 % / Previous period 1.6 % |
| Equity ratio | End of the current fiscal period 32.6 / End of previous period 32.2 |
| Total assets | ¥27,549 million |
| Net assets | ¥8,988 million |
| Cash flows from operating activities | ¥617 million |
| Cash flows from investing activities | ¥19 million |
| Cash flows from financing activities | ¥-240 million |
| Cash and cash equivalents at end of period | ¥5,698 million |
| Full-year earnings forecast | Net Sales ¥67,647 million (YoY +4.9%) / Operating profit ¥590 million (YoY -29.6%) / Ordinary income ¥632 million (YoY -30.5%) / Net income ¥354 million (YoY -42.6%) |
| Annual Dividend Forecast | ¥70 per share → ¥70 per share（0.0%） |
| Payout ratio | Current fiscal year 30 % / Next-year forecast 49 % |
| Shareholder Return Policy | Basically based on a consolidated dividend payout ratio of 30% |
| Segment revenue | Medical device sales ¥64,487 million (YoY +4.8%), Medical Equipment Manufacturing and Sales ¥219 million (YoY -18.0%), Medical Mall Business ¥72 million (YoY +6.4%) |
| Segment profit | Medical device sales ¥2,198 million (YoY +1.2%), Medical Equipment Manufacturing and Sales ¥-220 million, Medical Mall Business ¥5 million (YoY +750.6%) |
| Depreciation and amortization | ¥180 million |
| Impairment loss | None in the current period |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Reversal of allowance for doubtful accounts / Amount ¥36 million / Extraordinary loss Item Loss on step acquisition / Amount ¥3 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Material changes No / New Number of companies 1 / Company name Microsonic Corporation / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 2,553,000 Shares |
| Treasury Shares at Period-End | 86,958 Shares |
| Factors Behind Changes in Business Performance | 売上高は、放射線機器等の設備投資需要の増加、検査・手術件数の増加、株式会社鹿児島オルソ・メディカルの整形外科分野の売上増加等により増加した。利益面では、賃上げによる人件費2億20百万円の増加、物流コスト6千万円の上昇、マイクロソニック株式会社の研究開発費1億64百万円の計上等により販売費及び一般管理費が増加し、営業利益及び経常利益は減少した。 |
Items this document does not state (3)
Revision to Earnings ForecastRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.売上高は、放射線機器などの設備投資需要の増加、検査・手術件数の増加、株式会社鹿児島オルソ・メディカルの整形外科分野の売上増加により増加しました。営業利益は、賃上げによる人件費2億20百万円の増加、物流コスト6千万円の上昇、マイクロソニック株式会社の研究開発費1億64百万円の計上などにより減少しました。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.